The Wood on Clinuvel
Tuesday, 08 July, 2008
Clinuvel Pharmaceuticals [ASX: CUV] has set in train its plan to add international expertise to its board, with the appointment of a new non-executive director.
Jack Wood was appointed to the position today. Wood currently sits on the board of two Canadian biotechnology companies, Engene and QLT.
He also has experience in the Australian pharmaceutical sector, including eight years serving in various executive positons at CSL from 1992-2000.
Clinuvel is seeking international expertise in anticipation of the commercialisation of its photoprotective drug afamelanotide (CUV1647).
Protein-based therapy helps the body remove harmful cells
Scientists have created a protein-based therapeutic tool that could change the way we treat...
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
